ZYUS Life Sciences Appoints Dr. Julie Stakiw as Chief Medical Officer to Advance Phase 2 Oncology Pain Program and Strengthen Clinical Development Leadership In a pivotal step toward accelerating its…
JCR Pharmaceuticals and Acumen Pharmaceuticals Forge Strategic Partnership to Develop a Blood-Brain Barrier-Penetrating Alzheimer’s Therapy Using J-Brain Cargo® Platform JCR Pharmaceuticals Co., Ltd. (TSE: 4552), a Japan-based global specialty biopharmaceutical…
PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO)…
Reflow Medical Receives FDA De Novo Clearance for Spur Stent System, Marking a Breakthrough in Treatment of Below-the-Knee Peripheral Arterial Disease Reflow Medical, Inc., a pioneering company in the development…
CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully…
Samsung Bioepis Unveils European Policy Whitepaper to Bridge Gaps Hindering Biosimilar Access and Market Sustainability Samsung Bioepis Co., Ltd. has published a comprehensive whitepaper titled “Solving the Biosimilar Void in…
New Guidelines Expand Access to Advanced Liver Imaging and Transplant Evaluations Using Contrast-Enhanced Ultrasound A new policy change is being hailed by medical experts as a transformative advancement in the…
HistoSonics Expands Access to Groundbreaking Non-Invasive Liver Tumor Treatment as Highmark Covers Histotripsy for 7 Million Members In a pivotal development for patients battling liver tumors, HistoSonics, the medical technology…
Acadia Pharmaceuticals Unveils Ambitious Growth Strategy, Eyes $12 Billion Pipeline with Female-Led R&D Powerhouse More than three decades after its founding in 1993, Acadia Pharmaceuticals is embracing a bold new…
Takeda’s Oveporexton Achieves Landmark Phase 3 Success in Narcolepsy Type 1, Paving Way for First-in-Class Orexin Therapy Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced a major milestone in its development…
ViiV Healthcare Broadens Voluntary Licensing Deal with MPP to Include Long-Acting Injectable HIV Treatment in Global Access Push GSK plc (LSE/NYSE: GSK) announced that its majority-owned subsidiary, ViiV Healthcare—a global…
Baxdrostat Achieves Positive Results in Phase III BaxHTN Trial, Demonstrating Significant Blood Pressure Reduction in Patients with Uncontrolled or Resistant Hypertension AstraZeneca has announced promising top-line results from its pivotal…